| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Daily Oral Tablet, Tarceva (Erlotinib), For Advanced Non-Small Cell Lung Cancer NEW YORK, NY -- November 24, 2004 -- OSI Pharmaceuticals, Inc. and Genentech, Inc. have just announced that the U.S. Food and Drug Administration (FDA) has approved, Tarceva™ (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Tarceva is an oral tablet indicated for daily administration and is available as of Tuesday November 23, 2004. Tarceva is the only drug in the epidermal growth factor receptor (EGFR) class to demonstrate in a Phase III clinical trial an increase in survival in advanced NSCLC patients. According to the World Health Organization, there are more than 1.2 million cases worldwide of lung and bronchial cancer each year, causing approximately 1.1 million deaths annually. And according to the National Cancer Institute, lung cancer is the single largest cause of cancer deaths in the United States and is responsible for nearly 30 percent of cancer deaths in this country. NSCLC is the most common form of the disease and accounts for almost 80 percent of all lung cancers.
SOURCE: Genentech, Inc.
|